{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:39:59Z","timestamp":1793295599354,"version":"4.5.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T00:00:00Z","timestamp":1391126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"name":"Wellcome Trust of Great Britain"}],"content-domain":{"domain":["ijaaonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.ijantimicag.2014.01.005","type":"journal-article","created":{"date-parts":[[2014,2,3]],"date-time":"2014-02-03T05:45:37Z","timestamp":1391406337000},"page":"310-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":274,"title":["Treatment and prophylaxis of melioidosis"],"prefix":"10.1016","volume":"43","author":[{"given":"David","family":"Dance","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0005","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4269\/ajtmh.2010.10-0038","article-title":"Increasing incidence of human melioidosis in northeast Thailand","volume":"82","author":"Limmathurotsakul","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0010","doi-asserted-by":"crossref","first-page":"e900","DOI":"10.1371\/journal.pntd.0000900","article-title":"The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study","volume":"4","author":"Currie","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2014.01.005_bib0015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0035-9203(08)70002-6","article-title":"The global distribution of Burkholderia pseudomallei and melioidosis: an update","volume":"102","author":"Currie","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0020","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3201\/eid1906.120717","article-title":"Human melioidosis, Malawi, 2011","volume":"19","author":"Katangwe","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/jac\/24.3.295","article-title":"The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment","volume":"24","author":"Dance","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0030","doi-asserted-by":"crossref","first-page":"e9196","DOI":"10.1371\/journal.pone.0009196","article-title":"Growing Burkholderia pseudomallei in biofilm stimulating conditions significantly induces antimicrobial resistance","volume":"5","author":"Sawasdidoln","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0035","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ijantimicag.2011.12.010","article-title":"Diffusion and activity of antibiotics against Burkholderia pseudomallei biofilms","volume":"39","author":"Pibalpakdee","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0040","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1128\/AAC.00721-13","article-title":"In vitro activities of amoxicillin-clavulanate, doxycycline, ceftazidime, imipenem, and trimethoprim-sulfamethoxazole against biofilm of Brazilian strains of Burkholderia pseudomallei","volume":"57","author":"Bandeira Tde","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0045","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1128\/AAC.00953-10","article-title":"Adaptation and antibiotic tolerance of anaerobic Burkholderia pseudomallei","volume":"55","author":"Hamad","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0050","series-title":"Melioidosis","first-page":"217","article-title":"Review of 686 cases and presentation of a new clinical classification","author":"Punyagupta","year":"1989"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0055","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/infdis\/153.1.167","article-title":"In vitro susceptibility of strains of Pseudomonas pseudomallei isolated in Thailand and Hong Kong to some newer \u03b2-lactam antibiotics and quinolone derivatives","volume":"153","author":"Chau","year":"1986","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0060","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(89)90768-X","article-title":"Halving of mortality of severe melioidosis by ceftazidime","volume":"2","author":"White","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0065","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1128\/AAC.36.1.158","article-title":"Multicenter prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis","volume":"36","author":"Sookpranee","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0070","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1086\/444456","article-title":"Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis","volume":"41","author":"Chierakul","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0075","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/520010","article-title":"Addition of trimethoprim-sulfamethoxazole to ceftazidime during parenteral treatment of melioidosis is not associated with a long-term outcome benefit","volume":"45","author":"Chierakul","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0080","doi-asserted-by":"crossref","DOI":"10.3201\/eid1812.120638","article-title":"Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infection, 2010","volume":"18","author":"Lipsitz","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0085","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/clinids\/19.5.846","article-title":"Ceftazidime vs. amoxicillin\/clavulanate in the treatment of severe melioidosis","volume":"19","author":"Suputtamongkol","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0090","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jac\/24.6.1012","article-title":"The activity of amoxycillin\/clavulanic acid against Pseudomonas pseudomallei","volume":"24","author":"Dance","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0095","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/jac\/dkl389","article-title":"Pharmacokinetic and pharmacodynamic assessment of co-amoxiclav in the treatment of melioidosis","volume":"58","author":"Chierakul","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0100","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4269\/ajtmh.2008.78.208","article-title":"Consensus guidelines for dosing of amoxicillin-clavulanate in melioidosis","volume":"78","author":"Cheng","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0105","first-page":"158","article-title":"In-vitro susceptibility of Burkholderia pseudomallei to cefoperazone-sulbactam combination","volume":"52","author":"Koay","year":"1997","journal-title":"Med J Malaysia"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1086\/320878","article-title":"Randomized, double-blind, controlled study of cefoperazone-sulbactam plus cotrimoxazole versus ceftazidime plus cotrimoxazole for the treatment of severe melioidosis","volume":"33","author":"Chetchotisakd","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0115","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1086\/338722","article-title":"The role of cefoperazone-sulbactam for treatment of severe melioidosis","volume":"34","author":"Apisarnthanarak","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0120","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1086\/517787","article-title":"Empirical cephalosporin treatment of melioidosis","volume":"28","author":"Chaowagul","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0125","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1086\/338723","article-title":"Reply","volume":"34","author":"Chetchotisakd","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0130","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2125.2000.00179.x","article-title":"Pharmacokinetic\u2013pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis","volume":"50","author":"Angus","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0135","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-3156.2004.01244.x","article-title":"Out of hospital treatment of patients with melioidosis using ceftazidime in 24h elastomeric infusors, via peripherally inserted central catheters","volume":"9","author":"Huffam","year":"2004","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0140","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1016\/j.ijid.2012.12.004","article-title":"Providing outpatient parenteral antibiotic therapy (OPAT) to facilitate effective treatment of melioidosis","volume":"17","author":"Seetoh","year":"2013","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0145","series-title":"7th World Melioidosis Congress","article-title":"Intensive phase treatment duration and rates of recrudescence and relapse in melioidosis","author":"Pitman","year":"2013"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0150","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jac\/37.3.611","article-title":"In-vitro activity of carbapenem antibiotics against \u03b2-lactam susceptible and resistant strains of Burkholderia pseudomallei","volume":"37","author":"Smith","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0155","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/AAC.39.10.2356","article-title":"Postantibiotic effects and Burkholderia (Pseudomonas) pseudomallei: evaluation of current treatment","volume":"39","author":"Walsh","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0160","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/520219","article-title":"Comparison of imipenem and ceftazidime as therapy for severe melioidosis","volume":"29","author":"Simpson","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0165","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1086\/315306","article-title":"Differential antibiotic-induced endotoxin release in severe melioidosis","volume":"181","author":"Simpson","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0170","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1128\/AAC.48.5.1763-1765.2004","article-title":"Outcomes of patients with melioidosis treated with meropenem","volume":"48","author":"Cheng","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0175","doi-asserted-by":"crossref","first-page":"6032","DOI":"10.1128\/JCM.43.12.6032-6034.2005","article-title":"Recurrent melioidosis in patients in northeast Thailand is frequently due to reinfection rather than relapse","volume":"43","author":"Maharjan","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0180","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1086\/507632","article-title":"Risk factors for recurrent melioidosis in northeast Thailand","volume":"43","author":"Limmathurosakul","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0185","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/jac\/24.3.311","article-title":"Interactions in vitro between agents used to treat melioidosis","volume":"24","author":"Dance","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0190","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0255-0857(21)01773-4","article-title":"In vitro interactions between cotrimoxazole and doxycycline in Burkholderia pseudomallei: how important is this combination in maintenance therapy of melioidosis?","volume":"27","author":"Saraya","year":"2009","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0195","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/0035-9203(95)90104-3","article-title":"A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline, and co-trimoxazole for the oral maintenance treatment of melioidosis","volume":"89","author":"Rajchanuvong","year":"1995","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0200","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0035-9203(97)90044-4","article-title":"Oral fluoroquinolones for maintenance treatment of melioidosis","volume":"91","author":"Chaowagul","year":"1997","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0205","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.2001.64.24","article-title":"Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with cotrimoxazole plus doxycycline","volume":"64","author":"Chetchotisakd","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0210","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1086\/520218","article-title":"A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis","volume":"29","author":"Chaowagul","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0215","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1128\/AAC.49.10.4020-4025.2005","article-title":"Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy of melioidosis","volume":"49","author":"Chaowagul","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0220","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1128\/AAC.01301-08","article-title":"Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis","volume":"53","author":"Cheng","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0225","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1086\/318116","article-title":"Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature","volume":"31","author":"Currie","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0230","doi-asserted-by":"crossref","first-page":"927","DOI":"10.4269\/ajtmh.2012.12-0136","article-title":"Outcomes of patients with melioidosis treated with cotrimoxazole alone for eradication therapy","volume":"87","author":"Chusri","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0235","article-title":"Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial","author":"Chetchotisakd","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0240","article-title":"Melioidosis: refining management of a tropical time bomb","author":"Fisher","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0245","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/jac\/dki151","article-title":"Trimethoprim\/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei","volume":"55","author":"Wuthiekanun","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0250","series-title":"7th World Melioidosis Congress","article-title":"Co-trimoxazole resistance in Burkholderia pseudomallei from the Lao PDR, Cambodia and northern Australia","author":"Dance","year":"2013"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0255","first-page":"856","article-title":"Comparison between the antimicrobial susceptibility of Burkholderia pseudomallei to trimethoprim-sulfamethoxazole by standard disk diffusion method and by minimal inhibitory concentration determination","volume":"83","author":"Lumbiganon","year":"2000","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0260","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0924-8579(02)00016-X","article-title":"A comparison of antibiotic susceptibility testing methods for cotrimoxazole with Burkholderia pseudomallei","volume":"19","author":"Piliouras","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0265","series-title":"Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline","author":"Clinical and Laboratory Standards Institute","year":"2010"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0270","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1128\/AAC.44.3.693-696.2000","article-title":"A double-blind placebo-controlled study of an infusion of lexipafant (platelet-activating factor receptor antagonist) in patients with severe sepsis","volume":"44","author":"Suputtamongkol","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0275","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/QCO.0b013e32833fb88c","article-title":"Melioidosis: advances in diagnosis and treatment","volume":"23","author":"Cheng","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0280","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/380456","article-title":"Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis","volume":"38","author":"Cheng","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0285","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1086\/519261","article-title":"A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand","volume":"45","author":"Cheng","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0290","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0002-9343(68)90060-0","article-title":"Laboratory acquired melioidosis","volume":"44","author":"Green","year":"1968","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0295","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJM198111053051907","article-title":"Laboratory-acquired infection with Pseudomonas pseudomallei (melioidosis)","volume":"305","author":"Schlech","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0300","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.3201\/eid1407.071501","article-title":"Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei","volume":"14","author":"Peacock","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0305","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/jac\/dkm527","article-title":"Pre- and post-exposure prophylaxis of experimental Burkholderia pseudomallei infection with doxycycline, amoxicillin\/clavulanic acid and co-trimoxazole","volume":"61","author":"Sivalingam","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0310","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ijantimicag.2013.02.007","article-title":"Trimethoprim\/sulfamethoxazole (co-trimoxazole) prophylaxis is effective against acute murine inhalational melioidosis and glanders","volume":"41","author":"Barnes","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0315","doi-asserted-by":"crossref","first-page":"858","DOI":"10.4269\/ajtmh.2011.10-0618","article-title":"Repeat blood culture positive for B. pseudomallei indicates an increased risk of death from melioidosis","volume":"84","author":"Limmathurotsakul","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0320","unstructured":"World Bank. Lao PDR. http:\/\/data.worldbank.org\/country\/lao-pdr [accessed 08.01.14]."},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0325","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1086\/318713","article-title":"Melioidosis and Pandora's box in the Lao People's Democratic Republic","volume":"32","author":"Phetsouvanh","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0330","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1128\/AAC.00660-13","article-title":"The BpeEF-OprC efflux pump is responsible for widespread trimethoprim resistance in clinical and environmental Burkholderia pseudomallei isolates","volume":"57","author":"Podnecky","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0335","first-page":"121845","article-title":"The in vitro antibiotic susceptibility of Malaysian isolates of Burkholderia pseudomallei","author":"Ahmad","year":"2013","journal-title":"Int J Microbiol"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0340","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1128\/AAC.35.8.1635","article-title":"Pseudomonas pseudomallei resistance to \u03b2-lactam antibiotics due to alterations in the chromosomally encoded \u03b2-lactamase","volume":"35","author":"Godfrey","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0345","doi-asserted-by":"crossref","first-page":"945","DOI":"10.47102\/annals-acadmedsg.V39N12p945","article-title":"Development of ceftazidime resistance in Burkhoderia pseudomallei in a patient experiencing melioidosis with mediastinal lymphadenitis","volume":"39","author":"Kung","year":"2010","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0350","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/IDR.S35529","article-title":"Development of ceftazidime resistance in an acute Burkholderia pseudomallei infection","volume":"5","author":"Sarovich","year":"2012","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0355","doi-asserted-by":"crossref","first-page":"e30789","DOI":"10.1371\/journal.pone.0030789","article-title":"Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia","volume":"7","author":"Sarovich","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0360","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.1128\/AAC.05517-11","article-title":"Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand","volume":"55","author":"Wuthiekanun","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0365","doi-asserted-by":"crossref","first-page":"17165","DOI":"10.1073\/pnas.1111020108","article-title":"Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei","volume":"108","author":"Chantratita","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0370","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ijantimicag.2013.07.001","article-title":"In vitro antimicrobial susceptibility of clinical and environmental strains of Burkholderia pseudomallei from Brazil","volume":"42","author":"Bandeira Tde","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0375","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2217\/fmb.12.116","article-title":"Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis","volume":"7","author":"Schweizer","year":"2012","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0380","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1128\/AAC.00893-08","article-title":"In vitro activity of doripenem against Burkholderia pseudomallei","volume":"53","author":"Thamlikitkul","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0385","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ijantimicag.2011.02.001","article-title":"Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin","volume":"37","author":"Harris","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0390","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ijantimicag.2010.01.002","article-title":"In vitro activity of biapenem against Burkholderia pseudomallei","volume":"35","author":"Thamlikitkul","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0395","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ijantimicag.2013.06.016","article-title":"In vitro activity of tebipenem against Burkholderia pseudomallei","volume":"42","author":"Seenama","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0400","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1128\/AAC.50.4.1555-1557.2006","article-title":"In vitro activity of tigecycline against Burkholderia pseudomallei and Burkholderia thailandensis","volume":"50","author":"Thamlikitkul","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0405","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ijantimicag.2006.07.022","article-title":"Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model","volume":"28","author":"Feterl","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0410","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.diagmicrobio.2010.02.005","article-title":"Susceptibility of Burkholderia pseudomallei to tigecycline and other antimicrobials","volume":"67","author":"Sam","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0415","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijantimicag.2011.03.019","article-title":"In vitro activity of BAL30072 against Burkholderia pseudomallei","volume":"38","author":"Mima","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0420","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ijantimicag.2011.06.004","article-title":"In vitro activity of sitafloxacin against Burkholderia pseudomallei","volume":"38","author":"Thamlikitkul","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0425","doi-asserted-by":"crossref","first-page":"e2212","DOI":"10.1371\/journal.pntd.0002212","article-title":"Post-exposure therapeutic efficacy of COX-2 inhibition against Burkholderia pseudomallei","volume":"7","author":"Asakrah","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0430","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijantimicag.2009.05.012","article-title":"In vitro susceptibility of Burkholderia pseudomallei to antimicrobial peptides","volume":"34","author":"Kanthawong","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0435","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijantimicag.2011.06.002","article-title":"Antimicrobial activity of cathelicidin peptides against Burkholderia pseudomallei, the causative agent of melioidosis","volume":"38","author":"Sim","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0440","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijantimicag.2011.09.010","article-title":"Antimicrobial and antibiofilm activity of LL-37 and its truncated variants against Burkholderia pseudomallei","volume":"39","author":"Kanthawong","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0445","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s11274-013-1284-6","article-title":"A heterodimer comprised of two bovine lactoferrin antimicrobial peptides exhibits powerful bactericidal activity against Burkholderia pseudomallei","volume":"29","author":"Puknun","year":"2013","journal-title":"World J Microbiol Biotechnol"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0450","doi-asserted-by":"crossref","first-page":"e2267","DOI":"10.1371\/journal.pntd.0002267","article-title":"Antimicrobial action of the cyclic peptide bactenecin on Burkholderia pseudomallei correlates with efficient membrane permeabilization","volume":"7","author":"Madhongsa","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0455","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1128\/AAC.05885-11","article-title":"Sesquiterpene farnesol contributes to increased susceptibility to \u03b2-lactams in strains of Burkholderia pseudomallei","volume":"56","author":"Brilhante","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0460","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/infdis\/jir301","article-title":"Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis","volume":"204","author":"Easton","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0465","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1128\/CVI.05545-11","article-title":"Cationic liposomes extend the immunostimulatory effect of CpG oligodeoxynucleotide against Burkholderia pseudomallei infection in BALB\/c mice","volume":"19","author":"Puangpetch","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0470","first-page":"551","article-title":"Glycogen synthase kinase-3 inhibition improved survivability of mice infected with Burkholderia pseudomallei","volume":"29","author":"Tay","year":"2012","journal-title":"Trop Biomed"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0475","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1128\/AAC.02327-12","article-title":"Growth inhibition of pathogenic bacteria by sulfonylurea herbicides","volume":"57","author":"Kreisberg","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0480","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/dkq391","article-title":"In vitro activity of cethromycin against Burkholderia pseudomallei and investigation of mechanism of resistance","volume":"66","author":"Mima","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0485","doi-asserted-by":"crossref","first-page":"e1002587","DOI":"10.1371\/journal.ppat.1002587","article-title":"Nasal Acai polysaccharides potentiate innate immunity to protect against pulmonary Francisella tularensis and Burkholderia pseudomallei infections","volume":"8","author":"Skyberg","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0490","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/1871526511313020005","article-title":"Plant-based hydrocarbon esters from Tragia involucrata possess antimicrobial and anti-inflammatory activities","volume":"13","author":"Samy","year":"2013","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0495","first-page":"619","article-title":"Bioactivity of plant extracts against Burkholderia pseudomallei","volume":"6","author":"Panomket","year":"2012","journal-title":"Asian Biomed"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0500","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1471-2334-6-100","article-title":"In vitro antimicrobial activity of natural toxins and animal venoms tested against Burkholderia pseudomallei","volume":"6","author":"Samy","year":"2006","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0505","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/ml400034m","article-title":"Discovery of inhibitors of Burkholderia pseudomallei methionine aminopeptidase with antibacterial activity","volume":"4","author":"Wangtrakuldee","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0510","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3844\/ajisp.2011.39.53","article-title":"Monoclonal antibody-based therapeutics for melioidosis and glanders","volume":"7","author":"Kim","year":"2011","journal-title":"Am J Immunol"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0515","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1586\/eri.10.4","article-title":"Present and future therapeutic strategies for melioidosis and glanders","volume":"8","author":"Estes","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0520","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1751-7915.2012.00334.x","article-title":"When it comes to drug discovery not all Gram-negative bacterial biodefence pathogens are created equal: Burkholderia pseudomallei is different","volume":"5","author":"Schweizer","year":"2012","journal-title":"Microb Biotechnol"},{"key":"10.1016\/j.ijantimicag.2014.01.005_bib0525","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2217\/fmb.11.50","article-title":"Antimicrobials for bacterial bioterrorism agents","volume":"6","author":"Sarkar-Tyson","year":"2011","journal-title":"Future Microbiol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857914000181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857914000181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T02:19:50Z","timestamp":1688955590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857914000181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0924857914000181"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.01.005","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment and prophylaxis of melioidosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Author. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}